Epstein-Barr virus peptide-Human Leukocyte Antigen complex (EBV pHLA)

The Epstein-Barr virus (EBV) peptide-Human Leukocyte Antigen (HLA) complex is a molecular assembly formed when EBV-derived protein fragments are processed and presented on the cell surface by HLA molecules. This complex is the fundamental unit recognized by the cellular immune system, particularly CD8+ T-cells, to distinguish healthy cells from those infected with EBV or transformed into EBV-associated malignancies (Cohen, 2000). EBV is a ubiquitous herpesvirus linked to several cancers, including nasopharyngeal carcinoma and various lymphomas, as well as autoimmune conditions like multiple sclerosis (Bittel et al., 2022). Therapeutic strategies targeting these complexes include adoptive cell therapies like tabelecleucel, which uses allogeneic EBV-specific T-cells to treat post-transplant lymphoproliferative disorder (Dhillon, 2023). The specificity of these therapies depends on the precise match between the T-cell receptor and the specific peptide-HLA combination, making patient HLA typing a critical component of treatment (Haque et al., 2007). Beyond oncology, these complexes are being investigated as targets for vaccines and TCR-T therapies aimed at controlling chronic EBV infection and its associated complications. Challenges in targeting this complex include the potential for HLA downregulation by tumor cells and the risk of off-target cross-reactivity with similar self-peptides.

Other names

EBV peptide-MHC complexEBV pMHCEBV-specific peptide-MHC complexEBV-derived peptides on HLAEBV antigen-HLA complexEpstein-Barr virus pHLA

Therapeutic agents targeting the EBV peptide-HLA complex, such as EBV-specific T-cells or TCR-engineered cells, utilize T-cell receptors to specifically bind the viral peptide presented within the HLA groove. This binding event triggers the formation of an immunological synapse, leading to the release of cytotoxic granules containing perforin and granzymes, which induce programmed cell death in the target cell (Haque et al., 2007; Dhillon, 2023).